Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

@article{Sjstrm1999DocetaxelCW,
  title={Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.},
  author={Johanna Sj{\"o}str{\"o}m and Carl Blomqvist and Henning T. Mouridsen and Anna Pluzańska and S Ottosson-L{\"o}nn and N. O. Bengtsson and Bj\orn Ostenstad and Ingvil Mjaaland and M Palm-Sj{\"o}vall and Erik Andreas Wist and Vahur Valvere and Harald Anderson and Jonas Bergh},
  journal={European journal of cancer},
  year={1999},
  volume={35 8},
  pages={1194-201}
}
The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure. A randomised multicentre trial was conducted in 283 patients with advanced breast cancer who had failed previous anthracycline treatment. Docetaxel at a dose of 100 mg/m2 every 3 weeks (n = 143) was compared with sequential methotrexate and 5-fluorouracil (MF; n = 139) given at day 1 and 8 every 3 weeks at dosages of 200 mg/ m2… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Connections & Topics

Mentioned Connections BETA
AstheniaNo subtypeEdema
Significantly more side - effects ( leucopenia , infections , neuropathy , oedema , asthenia , skin , nail changes , alopecia ) were seen in the docetaxel than in the MF group .
EdemaNo subtypeAsthenia
Significantly more side - effects ( leucopenia , infections , neuropathy , oedema , asthenia , skin , nail changes , alopecia ) were seen in the docetaxel than in the MF group .
Based on the response rate and the primary endpoint of TTP , docetaxel is superior to sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Docetaxel at a dose of 100 mg / m2 every 3 weeks ( n = 143 ) was compared with sequential methotrexate and 5-fluorouracil ( MF ; n = 139 ) given at day 1 and 8 every 3 weeks at dosages of 200 mg/ m2 and 600 mg / m2 , respectively .
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure : a randomised phase III study with crossover on progression by the Scandinavian Breast Group .
The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Docetaxel at a dose of 100 mg / m2 every 3 weeks ( n = 143 ) was compared with sequential methotrexate and 5-fluorouracil ( MF ; n = 139 ) given at day 1 and 8 every 3 weeks at dosages of 200 mg/ m2 and 600 mg / m2 , respectively .
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure : a randomised phase III study with crossover on progression by the Scandinavian Breast Group .
Based on the response rate and the primary endpoint of TTP , docetaxel is superior to sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure : a randomised phase III study with crossover on progression by the Scandinavian Breast Group .
The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Based on the response rate and the primary endpoint of TTP , docetaxel is superior to sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure : a randomised phase III study with crossover on progression by the Scandinavian Breast Group .
The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Based on the response rate and the primary endpoint of TTP , docetaxel is superior to sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure : a randomised phase III study with crossover on progression by the Scandinavian Breast Group .
The aim of this study was to compare the efficacy and tolerability of docetaxel to methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
Based on the response rate and the primary endpoint of TTP , docetaxel is superior to sequential methotrexate and 5-fluorouracil in advanced breast cancer after anthracycline failure .
All Topics